{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:18:28Z","timestamp":1788920308410,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16\u201359 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one \u201cat-risk\u201d (chronic disease) or \u201chigh-risk\u201d (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63\u20133.13) person years. For individuals aged 16\u201359 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41\u20130.48) in 2016 to 1.24% (95% CI 1.18\u20131.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09\u20132.40) vs. 0.90% (95% CI 0.85\u20130.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10\u20132.41) vs. 0.90% (95% CI 0.84\u20130.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8\u2013702.0)) compared to at-risk conditions (435.5 days (IQR 196.3\u2013758.8)).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16\u201359 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16\u201359 years of age developing conditions with higher susceptibility to pneumococcal infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07736-1","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T13:04:28Z","timestamp":1664370268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pneumococcal vaccination coverage in individuals (16\u201359 years) with a newly diagnosed risk condition in Germany"],"prefix":"10.1186","volume":"22","author":[{"given":"Arijita","family":"Deb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9l\u00e8ne","family":"Podmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Galetzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawab","family":"Qizilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Haeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Boellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"7736_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12879-015-1162-y","volume":"15","author":"SI Pelton","year":"2015","unstructured":"Pelton SI, Shea KM, Farkouh RA, Strutton DR, Braun S, Jacob C, Klok R, Gruen ES, Weycker D. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015;15:470.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"7736_CR2","first-page":"71","volume":"67","author":"T Welte","year":"2012","unstructured":"Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorac Surg Clin. 2012;67(1):71\u20139.","journal-title":"Thorac Surg Clin"},{"issue":"5","key":"7736_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1080\/21645515.2018.1428507","volume":"14","author":"L Willem","year":"2018","unstructured":"Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, Verhaegen J, Goossens H, Beutels P. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Hum Vacc Immunothera. 2018;14(5):1218\u201329.","journal-title":"Hum Vacc Immunothera"},{"issue":"11","key":"7736_CR4","first-page":"1057","volume":"68","author":"A Torres","year":"2013","unstructured":"Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorac Surg Clin. 2013;68(11):1057\u201365.","journal-title":"Thorac Surg Clin"},{"key":"7736_CR5","unstructured":"World Health Organization (WHO).\u00a0Global status report on noncommunicable diseases. 2020: World Health Organization; 2020."},{"key":"7736_CR6","unstructured":"Institute for Health Metrics and Evaluation (IHME). Findings from the global burden of disease study 2017. The Lancet. 2018."},{"key":"7736_CR7","unstructured":"German Standing Committee on Vaccination at the Robert Koch Institute. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute-2017\/2018. Epidemiol Bull.\u00a02017: 34."},{"issue":"10","key":"7736_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12325-014-0157-1","volume":"31","author":"P Castiglia","year":"2014","unstructured":"Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014;31(10):1011\u201344.","journal-title":"Adv Ther"},{"key":"7736_CR9","unstructured":"German Standing Committee on Vaccination at the Robert Koch Institute. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute-2016\/2017. Epidemiol Bull.\u00a02016; 34."},{"issue":"44","key":"7736_CR10","first-page":"743","volume":"110","author":"U Theidel","year":"2013","unstructured":"Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850 000 individuals. Dtsch Arztebl Int. 2013;110(44):743\u201350.","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"7736_CR11","doi-asserted-by":"publisher","first-page":"e0220848","DOI":"10.1371\/journal.pone.0220848","volume":"14","author":"N Schmedt","year":"2019","unstructured":"Schmedt N, Schiffner-Rohe J, Sprenger R, Walker J, von Eiff C, H\u00e4ckl D. Pneumococcal vaccination rates in immunocompromised patients\u2014a cohort study based on claims data from more than 200,000 patients in Germany. PLoS ONE. 2019;14(8):e0220848.","journal-title":"PLoS ONE"},{"issue":"3","key":"7736_CR12","doi-asserted-by":"publisher","first-page":"e0265433","DOI":"10.1371\/journal.pone.0265433","volume":"17","author":"R Sprenger","year":"2022","unstructured":"Sprenger R, H\u00e4ckl D, Kossack N, Schiffner-Rohe J, Wohlleben J, von Eiff C. Pneumococcal vaccination rates in immunocompromised patients in Germany: a retrospective cohort study to assess sequential vaccination rates and changes over time. PLoS ONE. 2022;17(3):e0265433.","journal-title":"PLoS ONE"},{"key":"7736_CR13","doi-asserted-by":"crossref","unstructured":"Bothe T, Walker J, Kr\u00f6ger C. Gender-related differences in health-care and economic costs for eating disorders: a comparative cost-development analysis for anorexia and bulimia nervosa based on anonymized claims data. Int J Eat Disord.\u00a02021.","DOI":"10.1002\/eat.23610"},{"issue":"1","key":"7736_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25(1):106\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"7736_CR15","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3201\/eid0812.010497","volume":"8","author":"S Rehmet","year":"2002","unstructured":"Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999\u20132000. Emerg Infect Dis. 2002;8(12):1442\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"7736_CR16","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2337\/dc08-0138","volume":"31","author":"JB Kornum","year":"2008","unstructured":"Kornum JB, Thomsen RW, Riis A, Lervang H-H, Sch\u00f8nheyder HC, S\u00f8rensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541\u20135.","journal-title":"Diabetes Care"},{"issue":"1","key":"7736_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jinf.2012.02.017","volume":"65","author":"AJ van Hoek","year":"2012","unstructured":"van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17\u201324.","journal-title":"J Infect"},{"key":"7736_CR18","unstructured":"Public Health England. Pneumococcal: the Green book of immunisation, Chap. 25. 2020."},{"issue":"1","key":"7736_CR19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1186\/s12889-020-09613-5","volume":"20","author":"I Matthews","year":"2020","unstructured":"Matthews I, Lu X, Xia Q, Black W, Nozad B. Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis. BMC Public Health. 2020;20(1):1584.","journal-title":"BMC Public Health"},{"issue":"27","key":"7736_CR20","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1016\/j.vaccine.2020.04.052","volume":"38","author":"J Neufeind","year":"2020","unstructured":"Neufeind J, Betsch C, Habersaat KB, Eckardt M, Schmid P, Wichmann O. Barriers and drivers to adult vaccination among family physicians\u2014insights for tailoring the immunization program in Germany. Vaccine. 2020;38(27):4252\u201362.","journal-title":"Vaccine"},{"issue":"1","key":"7736_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12875-016-0502-3","volume":"17","author":"CJ Klett-Tammen","year":"2016","unstructured":"Klett-Tammen CJ, Krause G, von Lengerke T, Castell S. Advising vaccinations for the elderly: a cross-sectional survey on differences between general practitioners and physician assistants in Germany. BMC Fam Pract. 2016;17(1):98.","journal-title":"BMC Fam Pract"},{"key":"7736_CR22","unstructured":"Administering. Pneumococcal Vaccines. https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/administering-vaccine.html."},{"key":"7736_CR23","unstructured":"COVID-19 vaccines. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines."},{"key":"7736_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57\u201362.","journal-title":"Public Health"},{"issue":"6","key":"7736_CR25","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.4161\/hv.28450","volume":"10","author":"S Hense","year":"2014","unstructured":"Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729\u201333.","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07736-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T13:09:38Z","timestamp":1664370578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07736-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7736"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07736-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"De-identified SHI data were used for this research. The use of such data is not subject to ethics committee approval in Germany. The study obtained approval from the internal InGef Scientific Research Group which considers both ethical and scientific aspects of the intended study and has waived the need for informed consent. The study was carried out in accordance with relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This research was sponsored and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD). OXON Epidemiology, an independent contract research organization, was contracted by MSD to design and conduct the study in collaboration with WIG2. InGef acted as subcontractor and received funding from WIG2 for the execution of the study. All authors declare financial and non-financial conflicts of interest. KDJ and TW are employed by MSD USA, and TB is employed by MSD in Germany (Levelingstr. 4a, 81673 M\u00fcnchen). AD was employed by MSD USA at the time of the study. BP, RB and NQ are employed by OXON Epidemiology. DH is employed by WIG2. DB is employed by InGef and WG was employed by InGef at the time of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"753"}}